Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
2 Top Biotech Stocks to Buy Right Now
09:45am, Saturday, 19'th Nov 2022
These two rank among the 10 largest pharmaceutical companies on the planet.
J&J's Gorsky and Merck's Frazier on working collaboratively to vaccinate people during pandemic
09:31am, Saturday, 19'th Nov 2022
Johnson & Johnson CEO Alex Gorsky and Merck CEO Ken Frazier discuss the importance of working together during the pandemic to develop an effective vaccine.
Merck to supply U.S. government with oral antiviral drug used to treat Covid
04:39am, Saturday, 19'th Nov 2022
Merck will supply an oral antiviral medication intended to treat mild to moderate Covid-19 to the U.S. government in a new procurement agreement. CNBC's Meg Tirrell reports.
3 Bargain Stocks You Can Buy Today and Hold Forever
10:15pm, Friday, 18'th Nov 2022 The Motley Fool
The low price only matters if the underlying company can be rebuilt as needed.
Credit Suisse Believes In This Pharma Giant's Low Risk Growth Against Uncertain Backdrop
07:08pm, Friday, 18'th Nov 2022 Benzinga
Credit Suisse has initiated coverage on Merck & Co Inc (NYSE: MRK) with an Outperform rating and a price target of $120.
The analysts note that Merck's high, consistent earnings growth, which is c
Sanofi's (SNY) Rare Anemia Drug Enjaymo Gets EU Approval
05:40pm, Friday, 18'th Nov 2022 Zacks Investment Research
Sanofi's (SNY) Enjaymo gets approval to treat hemolytic anemia in adult patients with cold agglutinin disease (CAD) in Europe.
3 Bargain Stocks You Can Buy Today and Hold Forever
05:15pm, Friday, 18'th Nov 2022
The low price only matters if the underlying company can be rebuilt as needed.
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
04:58pm, Friday, 18'th Nov 2022 Benzinga
Upgrades
According to Summit Insights Group, the prior rating for Applied Materials Inc (NASDAQ:AMAT) was changed from Hold to Buy. For the fourth quarter, Applied Materials had an EPS of $2.03, comp
What 13 Analyst Ratings Have To Say About Merck & Co
03:02pm, Friday, 18'th Nov 2022 Benzinga
Analysts have provided the following ratings for Merck & Co (NYSE:MRK) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
8
2
0
0
Last 30
Pharma Stock Roundup: RHHBY's Alzheimer's Study Failure, EU Nod for SNY's Enjaymo
12:50pm, Friday, 18'th Nov 2022 Zacks Investment Research
Roche's (RHHBY) late-stage Alzheimer's disease study on key pipeline candidate, gantenerumab fails. Sanofi's (SNY) Enjaymo to treat a rare form of anemia gets approval in Europe.
Tracking Ray Dalio's Bridgewater Associates 13F Portfolio - Q3 2022 Update
08:03am, Friday, 18'th Nov 2022 Seeking Alpha
Bridgewater Associates’ 13F portfolio value decreased from ~$23.60B to ~$19.75B this quarter. They increased Visa, Mondelez International, MasterCard, and Alphabet.
Analyst Expects 'Somewhat Smaller Effect Size' From Gossamer Bio's Upcoming PAH Trial
07:37pm, Thursday, 17'th Nov 2022 Benzinga
Raymond James maintains Outperform on Gossamer Bio Inc (NASDAQ: GOSS) with a price target down from $18 to $15.
The analyst expects a somewhat smaller effect size for seralutinib vs. sotatercept's
Merck (MRK) Outpaces Industry YTD: What's in Store for 2023?
04:21pm, Thursday, 17'th Nov 2022 Zacks Investment Research
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments keep Merck's (MRK) stock afloat in 2023.
Novartis (NVS) Reportedly Looking to Sell Its Business Units
03:01pm, Thursday, 17'th Nov 2022 Zacks Investment Research
Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.
Merck (MRK) Outpaces Industry YTD: What's in Store for 2023?
12:47pm, Thursday, 17'th Nov 2022
Strong sales of key products like Keytruda and Gardasil and positive pipeline/regulatory developments keep Merck's (MRK) stock afloat in 2023.
